Haemostasis: What Actually Happens When a Blood Vessel Is Damaged?

You remove a peripheral cannula, place gauze over the site and apply pressure. A few minutes later, the bleeding has stopped.

It is such a routine part of nursing care that it is easy to miss what has just happened underneath the gauze.

A blood vessel has been injured, yet blood has remained fluid everywhere else. Platelets have gathered at the damaged surface, coagulation has generated thrombin, fibrin has strengthened the developing plug, and regulatory mechanisms have helped keep that response local.

That balance is haemostasis.

Now imagine the site keeps oozing. The patient has new petechiae, their platelet count is very low, or you discover they are taking apixaban. Suddenly, haemostasis is no longer a list of coagulation factors from a lecture. It is something you can see at the bedside.

So rather than memorising the process as separate pathways, follow what happens from the moment the vessel is damaged.

What happens when the vessel is damaged?

An intact blood vessel is not simply a pipe carrying blood. Its endothelial lining helps maintain an antithrombotic surface so blood can circulate without clotting against the vessel wall. When that lining is disrupted, collagen and other subendothelial structures are exposed and the local environment changes.

The injured vessel can constrict, reducing blood flow through the area. At the same time, von Willebrand factor (VWF) helps platelets attach to the damaged surface, particularly under the shear forces created by flowing blood.

Circulating platelets are normally kept relatively inactive. At the injury they adhere, become activated and change shape. They release and generate mediators that recruit further platelets, while changes to their surface receptors allow them to bind to one another more effectively. A platelet-rich plug begins to cover the defect.

You may have learned this as primary haemostasis, but it is worth avoiding the idea that platelets complete one stage and coagulation starts afterwards. The processes overlap. Activated platelet surfaces support coagulation reactions, and thrombin generated during coagulation is itself a powerful platelet activator.

This is also why the pressure you apply after removing a cannula matters. Direct pressure mechanically reduces blood loss while the haemostatic response develops. If the site continues to bleed despite appropriate pressure, the question becomes wider than the puncture itself: what might be interfering with haemostasis in this patient?

How does the platelet plug become a stable clot?

The early platelet plug forms quickly, but it needs reinforcement. This is where coagulation and fibrin become particularly important.

Coagulation is often taught using the intrinsic, extrinsic and common pathways. That model remains useful for understanding coagulation factors and some laboratory tests, but it is not a literal picture of two independent cascades running inside a patient.

At vascular injury, exposure of tissue factor helps initiate coagulation. Enzyme reactions generate a small amount of thrombin, which then amplifies the response. Thrombin activates platelets and coagulation factors and converts soluble fibrinogen into fibrin. Fibrin strands form through and around the platelet plug, and Factor XIII cross-links the fibrin, strengthening the developing clot.

Effective haemostasis therefore depends on the vessel wall, platelets and coagulation proteins working together. That relationship gives you a useful clinical pattern when you look at how a patient is bleeding.

Platelet problems tend to produce mucocutaneous bleeding. Think of bleeding close to the surface or from mucous membranes: petechiae, purpura, easy bruising, epistaxis, gum bleeding, heavy menstrual bleeding or persistent oozing from venepuncture and cannula sites.

Coagulation factor deficiencies tend to produce deeper bleeding. Bleeding may occur into joints, producing haemarthroses, or into muscles and other deeper tissues, producing larger haematomas. This pattern is classically associated with severe factor deficiencies such as haemophilia.

Platelet problem → surface and oozing
Clotting factor problem → deeper bleeding

Keep that as a recognition pattern rather than a diagnostic rule. Presentations can overlap, and medicines or conditions affecting several parts of haemostasis may not fit neatly into either group. Its value is in helping you connect what you see with the physiology underneath it.

Why does the clot stay at the damaged vessel?

Thrombin generation is powerful. If the response simply amplified without control, repairing one small vessel injury could threaten the rest of the circulation. Haemostasis therefore has to do two things at once: generate enough clot to stop blood loss and prevent that clotting response from spreading unnecessarily.

Intact endothelium around the injury retains antithrombotic properties, while blood flow helps carry activated factors away from the site. Natural anticoagulant systems also limit amplification. Antithrombin inhibits several activated coagulation enzymes, the protein C system regulates factors Va and VIIIa, and tissue factor pathway inhibitor helps regulate tissue factor-driven coagulation.

This makes anticoagulant medicines easier to understand. They deliberately interfere with parts of coagulation to reduce harmful thrombosis. Warfarin interferes with vitamin K recycling and reduces functional synthesis of vitamin K-dependent coagulation factors. Apixaban and rivaroxaban inhibit activated factor X (factor Xa), while dabigatran directly inhibits thrombin.

For the patient, that can mean bleeding becomes more significant when vascular injury occurs. It does not mean every bruise or small bleed in somebody taking an anticoagulant is an emergency, but persistent, unexpected or significant bleeding needs assessment. The medicine, dose and timing of the last dose may matter, as can renal or hepatic function, other medicines and the wider clinical picture.

Liver disease shows why haemostasis cannot be reduced to a simple ‘clotting versus bleeding’ switch. The liver produces many proteins involved in coagulation as well as proteins that regulate it. Advanced liver disease can therefore disturb procoagulant and anticoagulant pathways together. Describing these patients as simply ‘auto-anticoagulated’ misses that complexity.

What happens when the clot is no longer needed?

A fibrin clot is a temporary repair, not a permanent structure. As healing progresses, the fibrin scaffold is remodelled and removed through fibrinolysis.

Plasminogen can be incorporated into the clot and converted to plasmin. Plasmin cleaves fibrin and helps dismantle the clot. This process is also regulated because dissolving a newly formed clot too early could restart bleeding.

That brings the physiology directly to a blood test students encounter frequently: D-dimer. D-dimer is produced when cross-linked fibrin is broken down. A raised result therefore tells you that fibrin formation and degradation have occurred, but it does not tell you why. It can be raised in circumstances other than venous thromboembolism, which is why ‘raised D-dimer equals clot’ is not a safe interpretation. In UK practice, D-dimer is used within diagnostic pathways that first consider clinical probability. NICE also advises considering an age-adjusted D-dimer threshold for people over 50 when assessing suspected venous thromboembolism.

Normal haemostasis is local and controlled. Thrombosis is different: a pathological clot forms within the circulation and can obstruct blood flow. At the other extreme, severe systemic illness can disrupt the whole balance. Disseminated intravascular coagulation (DIC) is an acquired, life-threatening disorder in which coagulation becomes activated systemically rather than remaining localised. Current International Society on Thrombosis and Haemostasis (ISTH) guidance describes DIC as involving systemic coagulation activation, dysregulated fibrinolysis and endothelial injury, leading to microthrombosis. As DIC progresses, patients may develop bleeding and/or organ dysfunction. Its presentation varies with the underlying cause and stage, so diagnosis depends on the clinical context together with laboratory findings rather than one isolated result. Management requires treatment of the underlying cause alongside appropriate supportive care.

As a student nurse, the important point is not to diagnose DIC or interpret an isolated D-dimer independently. It is to understand enough of the physiology to recognise when bleeding, bruising, deterioration or abnormal results do not fit the patient you expected and need escalation.

Back to the patient with the cannula

You remove the cannula and the site keeps bleeding despite appropriate pressure. You now have a physiological framework for thinking about what you are seeing rather than jumping straight to a diagnosis.

Is this one difficult puncture site, or is the patient bleeding elsewhere? Are there petechiae, purpura or new bruises? Is there gum bleeding, haematuria, melaena or bleeding from another line? What is happening to the platelet count and haemoglobin, and are there relevant coagulation results? Is the patient taking an anticoagulant or antiplatelet medicine? Do they have liver disease, severe infection or another condition that could disturb haemostasis? Most importantly, how is the patient clinically?

The appearance of the bleeding can give you clues. Fine petechiae and persistent mucosal or puncture-site oozing may make you think about platelet number or function. A history of large muscle haematomas or haemarthroses points you towards a different part of haemostasis. Neither pattern gives you the diagnosis, but both help you ask better questions.

Persistent bleeding should be managed and escalated according to its severity and local policy. Major haemorrhage is a clinical emergency and requires rapid multidisciplinary management.

The cannula site is therefore not really the lesson. The lesson is what has to happen underneath the gauze.

A vessel has to recognise injury locally. Platelets have to form an early plug. Thrombin and fibrin have to stabilise it. Regulatory mechanisms have to stop that response spreading through the circulation. Then, once repair is underway, fibrinolysis has to remove what is no longer needed.

That is haemostasis: not three disconnected topics called platelets, coagulation and fibrinolysis, but one controlled response that allows blood to remain fluid until a damaged vessel needs repairing.

References

British Society for Haematology (2022) Haematological management of major haemorrhage. London: British Society for Haematology. Last reviewed 22 July 2025.

Chapin, J.C. and Hajjar, K.A. (2015) ‘Fibrinolysis and the control of blood coagulation’, Blood Reviews, 29(1), pp. 17–24.

Iba, T. et al. (2025) ‘Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation’, Journal of Thrombosis and Haemostasis, 23(7), pp. 2356–2362. doi: 10.1016/j.jtha.2025.03.038.

National Institute for Health and Care Excellence (2020, updated 2023) Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE guideline NG158.

NHS (n.d.) Apixaban. NHS.

Palta, S., Saroa, R. and Palta, A. (2014) ‘Overview of the coagulation system’, Indian Journal of Anaesthesia, 58(5), pp. 515–523.

Versteeg, H.H. et al. (2013) ‘New fundamentals in hemostasis’, Physiological Reviews, 93(1), pp. 327–358.

Educational note: This article supports learning and clinical reasoning for student nurses. It does not replace local policy, clinical supervision or individual patient assessment.